The constant scramble for blockbuster ethical drugs by pharmaceutical companies, endeavors like the Human Genome Project, and the growth of such fields as proteomics and bioinformatics have kept ...
The U.S. life sciences sector is at a turning point, with a glut of new lab space and declining venture capital and federal funding further pushing developers to meet evolving kinds of demand, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback